Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudineadefovir combination therapy in patients with lamivudine- resistant chronic hepatitis B
1
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background/Aims: Quantitation of hepatitis B surface antigen (HBsAg) is an increasingly popular method to determinethe treatment response in chronic hepatitis B (CHB) patients. The clinical value of HBsAg level measurement duringrescue therapy for lamivudine (LMV)-resistant CHB patients have not been evaluated to date. Therefore, this studyinvestigated the correlation between HBsAg level and treatment response in LMV- resistant CHB patients treated withadefovir (ADV) add-on therapy. Methods: LMV-resistant CHB patients treated with LMV-ADV combination therapy for over 2 years were included. HBsAglevels were measured at 6 month intervals until 1 year, and annually thereafter. Treatment response was assessed bydetermining the virological response (VR, undetectable HBV DNA levels) during treatment. Results: Fifty patients were included, of which 40 showed a VR. HBsAg levels were not different significantly at baseline(4.0 vs. 3.6 Log10 IU/mL, P=0.072). However, the HBsAg level decreased after 6 months of treatment in patients with a VRand became different significantly between the groups thereafter (3.9 vs. 3.3 at 6 months, P=0.002; 3.8 vs. 3.2 at 1 year,P=0.004; 3.9 vs. 3.2 at 2 years, P=0.008; 3.7 vs. 3.1 at 3 years, P =0.020). Conclusions: The HBsAg level at 6 months after treatment can help predict treatment response.
Abstract
Background/Aims: Quantitation of hepatitis B surface antigen (HBsAg) is an increasingly popular method to determinethe treatment response in chronic hepatitis B (CHB) patients. The clinical value of HBsAg level measurement duringrescue therapy for lamivudine (LMV)-resistant CHB patients have not been evaluated to date. Therefore, this studyinvestigated the correlation between HBsAg level and treatment response in LMV- resistant CHB patients treated withadefovir (ADV) add-on therapy. Methods: LMV-resistant CHB patients treated with LMV-ADV combination therapy for over 2 years were included. HBsAglevels were measured at 6 month intervals until 1 year, and annually thereafter. Treatment response was assessed bydetermining the virological response (VR, undetectable HBV DNA levels) during treatment. Results: Fifty patients were included, of which 40 showed a VR. HBsAg levels were not different significantly at baseline(4.0 vs. 3.6 Log10 IU/mL, P=0.072). However, the HBsAg level decreased after 6 months of treatment in patients with a VRand became different significantly between the groups thereafter (3.9 vs. 3.3 at 6 months, P=0.002; 3.8 vs. 3.2 at 1 year,P=0.004; 3.9 vs. 3.2 at 2 years, P=0.008; 3.7 vs. 3.1 at 3 years, P =0.020). Conclusions: The HBsAg level at 6 months after treatment can help predict treatment response.
참고문헌 (42)
- Moucari R, "Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients", Hepatology (Baltimore, Md.), 49, pp.1151~1157 (2009)
- Perrillo R., "Editorial: Measurement of HBsAg concentration during antiviral therapy of hepatitis B: who, when, and why", Am J Gastroenterol, 106, pp.1774~1776 (2011)
- Brunetto MR, "Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B", Hepatology, 49, pp.1141~1150 (2009)
- Jung YK, "Change in serum hepatitis B surface antigen level and its clinical significance in treatment-naïve, hepatitis B e antigen-positive patients receiving entecavir", J Clin Gastroenterol, 44, pp.653~657 (2010)
- Lee JM, "Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir", Hepatology, 53, pp.1486~1493 (2011)
- Yeon JE, "Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil", Gut, 55, pp.1488~1495 (2006)
- DeLong ER, "Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach", Biometrics, 44, pp.837~845 (1988)
- Lavanchy D., "Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures", J Viral Hepat, 11, pp.97~107 (2004)
- Sang Soo Lee, "Type and cause of liver disease in Korea: single-center experience, 2005-2010", Clinical and Molecular Hepatology, 18(3), pp.309~315 (2012), 대한간학회
- Chae HB, "Current status of liver diseases in Korea: hepatitis B", The Korean J Hepatol, 15(Suppl 6), pp.S13~S24 (2009)
- Rotman Y, "Evaluation of the patient with hepatitis B", Hepatology, 49, pp.S22~S27 (2009)
- Nguyen T, "Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia", J Hepatol, 52, pp.508~513 (2010)
- Jaroszewicz J, "Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective", J Hepatol, 52, pp.514~522 (2010)
- Thompson AJ, "Serum hepatitis B surface antigen and hepatitis B e antigen titers:disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers", Hepatology, 51, pp.1933~1944 (2010)
- Janssen HL, "Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B?", Gut, 61, pp.641~645 (2012)
- Wursthorn K, "Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B", Hepatology, 44, pp.675~684 (2006)
- Chan HL, "Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response", Clin Gastroenterol Hepatol, 5, pp.1462~1468 (2007)
- Janssen HL, "Measurement of HBsAg to monitor hepatitis B viral replication in patients on alphainterferon therapy", Antiviral Res, 23, pp.251~257 (1994)
- Reijnders JG, "Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir", J Hepatol, 54, pp.449~454 (2011)
- Borgniet O1, "Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B", J Med Virol, 81, pp.1336~1342 (2009)
- 김정한, "HBsAg level and clinical course in patients with chronic hepatitis B treated with nucleoside analogue: five years of follow-up data", Clinical and Molecular Hepatology, 19(4), pp.409~416 (2013), 대한간학회[DOI]
- Korean Association for the Study of the Liver, "KASL Clinical Practice Guidelines: Management of chronic hepatitis B", Clin Mol Hepatol, 18, pp.109~162 (2012)
- European Association For The Study Of The Liver, "EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- Zoulim F, "Hepatitis B virus resistance to nucleos(t)ide analogues", Gastroenterology, 137, pp.1593~1608 (2009)
- Fung SK, "Virologic response and resistance to adefovir in patients with chronic hepatitis B", J Hepatol, 44, pp.283~290 (2006)
- Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B", Hepatology, 45, pp.307~313 (2007)
- Ijaz S, "Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy", J Med Virol, 80, pp.1160~1170 (2008)
- Vassiliadis TG, "Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study", J Gastroenterol Hepatol, 25, pp.54~60 (2010)
- Ryu HJ, "Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B", J Med Virol, 82, pp.1835~1842 (2010)
- Kim HJ, "Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy", J Gastroenterol Hepatol, 25, pp.1374~1380 (2010)
- Chung GE, "Addon adefovir is superior to a switch to entecavir as rescue therapy for Lamivudine-resistant chronic hepatitis B", Dig Dis Sci, 56, pp.2130~2136 (2011)
- 이현지, "Elecsys Hepatitis B Surface Antigen Quantitative Assay: Performance Evaluation and Correlation with Hepatitis B Virus DNA during 96 Weeks of Follow-up in Chronic Hepatitis B Patients", Annals of Laboratory Medicine, 32(6), pp.420~425 (2012), 대한진단검사의학회
- Lee JH, "Correlation between quantitative serum HBsAg and HBV DNA test in Korean patients who showed high level of HBsAg", J Clin Pathol, 63, pp.1027~1031 (2010)
- Su TH, "Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B", Antivir Ther, 15, pp.1133~1139 (2010)
- Ozaras R, "Correlation of quantitative assay of HBsAg and HBV DNA levels during chronic HBV treatment", Dig Dis Sci, 53, pp.2995~2998 (2008)
- Bartholomeusz A, "Hepatitis B virus mutations associated with antiviral therapy", J Med Virol, 78(Suppl 1), pp.S52~S55 (2006)
- Torresi J., "The virological and clinical significance of mutations in the overlapping envelope and polymerase genes of hepatitis B virus", J Clin Virol, 25, pp.97~106 (2002)
- Hsu CW, "Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance", Gastroenterology, 132, pp.543~550 (2007)
- Torresi J, "Reduced antigenicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy", Virology, 293, pp.305~313 (2002)
- Locarnini S, "Cellular and virological mechanisms of HBV drug resistance", J Hepatol, 44, pp.422~431 (2006)
- 김정한, "Hepatitis B Viral Surface Mutations in Patients with Adefovir Resistant Chronic Hepatitis B with A181T", V Polymerase Mutations, 2010, pp.25(2), 257~264[DOI]